CCDC110 Activators

Common CCDC110 Activators include, but are not limited to 5-Azacytidine CAS 320-67-2, Trichostatin A CAS 58880-19-6, Suberoylanilide Hydroxamic Acid CAS 149647-78-9, Sodium Butyrate CAS 156-54-7 and Resveratrol CAS 501-36-0.

CCDC110, or Coiled-Coil Domain Containing 110, is a protein-coding gene recognized for its role in protein binding. It's a member of the broader CCDC family, many of which are implicated in the pathogenesis of various diseases. In specific contexts, CCDC110 has been pinpointed as a potential prognostic marker in renal cancer, suggesting a favorable prognosis for those expressing it. Furthermore, its status as a novel human cancer/testis antigen means it can elicit both cellular and humoral immune responses. Intriguingly, its predicted cellular locations are the nucleus and cytoskeleton, reinforcing its importance in cellular dynamics.

The chemical class of CCDC110 Activators encompasses compounds designed to amplify the activity or expression of the CCDC110 protein. Such activators might enhance CCDC110 functionality by either direct interaction or modulation of associated signaling pathways. Their potential actions could lead to a boosted immune response against cancer cells, a change in cellular structural dynamics due to CCDC110's involvement in the cytoskeleton, or refined disease prognosis by adjusting CCDC110 expression levels. As CCDC110's involvement in tumor pathogenesis and other diseases becomes more evident, activators targeting this protein could offer a fresh perspective on novel strategies. Nonetheless, the comprehensive development and understanding of these activators warrant further rigorous research.